SYN 023

Drug Profile

SYN 023

Alternative Names: CTB 011/CTB 012; CTB 012/CTB 011; SYN-023

Latest Information Update: 15 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Synermore Biologics
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Rabies

Most Recent Events

  • 01 Dec 2017 Synermore Biologics completes a phase II trial in Rabies (Prevention, In volunteers) in USA (NCT02956746)
  • 13 Oct 2016 Discontinued - Phase-I for Rabies in China (IM)
  • 01 Aug 2016 Phase-II clinical trials in Rabies (Prevention, In volunteers) in USA (IM) (NCT02956746)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top